OLGA and OLGIM Stage System for Gastric Cancer
The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification
1 other identifier
observational
2,900
1 country
1
Brief Summary
To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 16, 2017
CompletedFirst Posted
Study publicly available on registry
December 20, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2022
CompletedApril 13, 2023
April 1, 2023
14.9 years
December 16, 2017
April 12, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk
To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification
per 1 year
Study Arms (2)
Gastric cancer
Patients who were diagnosed with gastric cancer
Control
Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
Eligibility Criteria
Patients who visited gastroenterology department complaining of gastrointestinal symptoms and underwent esophagogastroduodenoscopy (EGD)
You may qualify if:
- Control group
- those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy
- Gastric cancer group
- Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.
You may not qualify if:
- history of previous gastrointestinal surgery,
- any other malignancy
- cardia cancer
- who do not perform endoscopic biopsy
- pathologically proven gastric dysplasia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 463-707, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Officials Officials, Officials
Seoul National University Bundang Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 16, 2017
First Posted
December 20, 2017
Study Start
February 1, 2006
Primary Completion
January 1, 2021
Study Completion
January 1, 2022
Last Updated
April 13, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share